Matches in Wikidata for { <http://www.wikidata.org/entity/Q37161503> ?p ?o ?g. }
- Q37161503 description "article científic" @default.
- Q37161503 description "article scientifique" @default.
- Q37161503 description "articolo scientifico" @default.
- Q37161503 description "artigo científico" @default.
- Q37161503 description "artículu científicu espublizáu en 2008" @default.
- Q37161503 description "bilimsel makale" @default.
- Q37161503 description "scientific article published on 15 October 2008" @default.
- Q37161503 description "vedecký článok" @default.
- Q37161503 description "vetenskaplig artikel" @default.
- Q37161503 description "videnskabelig artikel" @default.
- Q37161503 description "vědecký článek" @default.
- Q37161503 description "wetenschappelijk artikel" @default.
- Q37161503 description "wissenschaftlicher Artikel" @default.
- Q37161503 description "наукова стаття, опублікована в жовтні 2008" @default.
- Q37161503 description "научни чланак" @default.
- Q37161503 description "مقالة علمية نشرت في 15 أكتوبر 2008" @default.
- Q37161503 name "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 name "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 name "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro." @default.
- Q37161503 type Item @default.
- Q37161503 label "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 label "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 label "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro." @default.
- Q37161503 prefLabel "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 prefLabel "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 prefLabel "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro." @default.
- Q37161503 P1433 Q37161503-FA3AFD64-193C-4AA4-85E9-5959ED8C87BA @default.
- Q37161503 P1476 Q37161503-020D605E-A71F-4BE0-BDE8-BF3F1841A9F6 @default.
- Q37161503 P2093 Q37161503-07987442-9B18-41C7-A280-5EB27F1B2AC6 @default.
- Q37161503 P2093 Q37161503-5848F3C9-F770-42F8-BA51-C112CCAFCF15 @default.
- Q37161503 P2093 Q37161503-591A7921-EC25-498A-B149-C8794AB676CF @default.
- Q37161503 P2093 Q37161503-71DE6A11-F448-43C4-ACB0-C26D4D0F160F @default.
- Q37161503 P2093 Q37161503-8BBD5304-5399-49D5-8CD9-77998819C395 @default.
- Q37161503 P2860 Q37161503-0AE257A0-AD6B-4E82-85B1-490FA0DB4194 @default.
- Q37161503 P2860 Q37161503-11D8F9F6-D05D-42F8-973D-A209A16958CF @default.
- Q37161503 P2860 Q37161503-186C4130-62D8-4B76-83BD-5FC31CF0CD05 @default.
- Q37161503 P2860 Q37161503-260813AF-42AD-4D33-A79E-CAE2FD30B4D8 @default.
- Q37161503 P2860 Q37161503-28D0450F-563B-4E61-ADA5-5C6832A7C479 @default.
- Q37161503 P2860 Q37161503-2A6052F0-053C-48A3-8A84-435CE8EA400C @default.
- Q37161503 P2860 Q37161503-3C812538-E10B-41DB-A8A0-FA7CB0419337 @default.
- Q37161503 P2860 Q37161503-43872C17-0C4C-4477-A5F4-691A0A0CD660 @default.
- Q37161503 P2860 Q37161503-4B2F0400-545C-4E58-B3D5-B2803815337C @default.
- Q37161503 P2860 Q37161503-50BA81D0-0ED4-4830-8FE7-7167C511C002 @default.
- Q37161503 P2860 Q37161503-516133A5-BF67-4F20-A53A-CA9B4A024FC9 @default.
- Q37161503 P2860 Q37161503-57582F0E-ACBE-4665-B168-2898F3538B0B @default.
- Q37161503 P2860 Q37161503-5FA0FCD2-339B-4DDF-8A85-5C13B9DC7BCC @default.
- Q37161503 P2860 Q37161503-62A4995D-617E-406B-90EF-FAF266D2C208 @default.
- Q37161503 P2860 Q37161503-6A839554-BD4A-4F01-AC3D-35E287945C51 @default.
- Q37161503 P2860 Q37161503-746FF81E-BCB9-4068-93A6-0F8D82F3B703 @default.
- Q37161503 P2860 Q37161503-793D92C5-452A-476F-801B-7FF429A7A032 @default.
- Q37161503 P2860 Q37161503-86CEF9F9-C0DA-431E-968B-22241989466D @default.
- Q37161503 P2860 Q37161503-A78ECDA8-36D4-4B5B-AD51-28339D9EE784 @default.
- Q37161503 P2860 Q37161503-ABDF4052-7B6E-4358-AAFB-A6BDA9421135 @default.
- Q37161503 P2860 Q37161503-ABFB5A48-3CB7-49B1-887F-7D2D88CDAF13 @default.
- Q37161503 P2860 Q37161503-BEE22ECA-9395-4907-9479-4A35CE6442D0 @default.
- Q37161503 P2860 Q37161503-C378C857-30C6-4D8F-9B21-8EBED1BBF7BD @default.
- Q37161503 P2860 Q37161503-D38D74A4-A9C3-4982-AC74-F9321864EA70 @default.
- Q37161503 P2860 Q37161503-DC2AC1CE-A98D-4235-85E7-048EE31608D5 @default.
- Q37161503 P2860 Q37161503-E1D06E3E-EEE6-4D28-BBCC-E3C036CF399B @default.
- Q37161503 P2860 Q37161503-EAB79753-85C8-4777-AF2F-50C9F7F9EECF @default.
- Q37161503 P2860 Q37161503-F2BC5899-BDD7-4745-B12B-7877E80130D8 @default.
- Q37161503 P304 Q37161503-879218BD-7444-4B7F-A14C-DEE40B89B474 @default.
- Q37161503 P31 Q37161503-21ADF28A-DF71-438D-AF08-F24839AE2ECE @default.
- Q37161503 P356 Q37161503-D0F23397-1EFB-440C-BFD4-F517C86A0121 @default.
- Q37161503 P407 Q37161503-EDF8E4CD-BEB4-4A91-9E2B-333F7A28D670 @default.
- Q37161503 P433 Q37161503-63513902-BCF4-43B6-B49A-F46D594552F0 @default.
- Q37161503 P478 Q37161503-EAFABAFF-0FFF-4132-B7FD-5742762962FD @default.
- Q37161503 P50 Q37161503-3D891140-3041-44D5-B3B3-57BE2187A86B @default.
- Q37161503 P577 Q37161503-9A6D7F3B-B6CF-4EBE-85E3-98BD000F4264 @default.
- Q37161503 P5875 Q37161503-19F24B3E-604E-458C-A687-D2075EAF9836 @default.
- Q37161503 P698 Q37161503-7A3B73C1-1737-496C-8175-00FDAE4208EB @default.
- Q37161503 P932 Q37161503-AC2BC48D-C447-4440-AFC8-48683E62E425 @default.
- Q37161503 P356 J.1365-2125.2008.03327.X @default.
- Q37161503 P698 19159406 @default.
- Q37161503 P1433 Q176044 @default.
- Q37161503 P1476 "Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro" @default.
- Q37161503 P2093 "Gorm Boje Jensen" @default.
- Q37161503 P2093 "Mads P G Korsgaard" @default.
- Q37161503 P2093 "Morten Grunnet" @default.
- Q37161503 P2093 "Per Sjøgren" @default.
- Q37161503 P2093 "Søren Fanoe" @default.
- Q37161503 P2860 Q26778461 @default.
- Q37161503 P2860 Q32045957 @default.
- Q37161503 P2860 Q33151147 @default.
- Q37161503 P2860 Q33154871 @default.
- Q37161503 P2860 Q34076987 @default.
- Q37161503 P2860 Q34155242 @default.
- Q37161503 P2860 Q34267653 @default.
- Q37161503 P2860 Q34331439 @default.
- Q37161503 P2860 Q34400282 @default.
- Q37161503 P2860 Q34562676 @default.
- Q37161503 P2860 Q34852212 @default.
- Q37161503 P2860 Q35095735 @default.
- Q37161503 P2860 Q36132411 @default.
- Q37161503 P2860 Q36181726 @default.
- Q37161503 P2860 Q36425985 @default.
- Q37161503 P2860 Q39348642 @default.
- Q37161503 P2860 Q44331678 @default.
- Q37161503 P2860 Q44333232 @default.
- Q37161503 P2860 Q44511776 @default.